These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28855210)

  • 1. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
    Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
    Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
    Stagg J; Divisekera U; McLaughlin N; Sharkey J; Pommey S; Denoyer D; Dwyer KM; Smyth MJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1547-52. PubMed ID: 20080644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
    Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
    J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
    Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy.
    Qiao Z; Li X; Kang N; Yang Y; Chen C; Wu T; Zhao M; Liu Y; Ji X
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30823477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
    Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD73 therapy impairs tumor angiogenesis.
    Allard B; Turcotte M; Spring K; Pommey S; Royal I; Stagg J
    Int J Cancer; 2014 Mar; 134(6):1466-73. PubMed ID: 23982901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
    Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
    Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.
    Mittal D; Caramia F; Michiels S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Loi S; Smyth MJ
    Cancer Res; 2016 Jan; 76(2):264-74. PubMed ID: 26744522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
    Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression.
    Sudo H; Tsuji AB; Sugyo A; Kurosawa G; Kurosawa Y; Alexander D; Tsuda H; Saga T; Higashi T
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 expression and fyn-dependent signaling on murine lymphocytes.
    Yamashita Y; Hooker SW; Jiang H; Laurent AB; Resta R; Khare K; Coe A; Kincade PW; Thompson LF
    Eur J Immunol; 1998 Oct; 28(10):2981-90. PubMed ID: 9808167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
    Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
    Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.